Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CYCC NASDAQ:LEXX NASDAQ:LSB NASDAQ:ONCO On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCYCCCyclacel Pharmaceuticals$7.12-4.6%$8.31$3.08▼$597.60$16.70M0.1584,166 shs81,174 shsLEXXLexaria Bioscience$1.03+6.7%$0.88$0.77▼$3.72$18.88M0.87179,866 shs157,799 shsLSBLakeShore Biopharma$0.84$0.92$0.59▼$8.60$17.44M0.5637,588 shs17,086 shsONCOOnconetix$2.78-3.1%$3.52$2.61▼$552.50$4.30M3.3686,594 shs11,755 shs The Best Nuclear Energy Stocks to BuyNuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCYCCCyclacel Pharmaceuticals-4.56%-13.49%-3.91%+28.29%-97.20%LEXXLexaria Bioscience+6.69%+17.01%+22.77%+4.57%-70.06%LSBLakeShore Biopharma0.00%+1.69%+26.79%-16.00%-82.13%ONCOOnconetix-3.14%-5.12%-5.44%-55.86%-99.37%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCYCCCyclacel Pharmaceuticals$7.12-4.6%$8.31$3.08▼$597.60$16.70M0.1584,166 shs81,174 shsLEXXLexaria Bioscience$1.03+6.7%$0.88$0.77▼$3.72$18.88M0.87179,866 shs157,799 shsLSBLakeShore Biopharma$0.84$0.92$0.59▼$8.60$17.44M0.5637,588 shs17,086 shsONCOOnconetix$2.78-3.1%$3.52$2.61▼$552.50$4.30M3.3686,594 shs11,755 shs The Best Nuclear Energy Stocks to BuyNuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCYCCCyclacel Pharmaceuticals-4.56%-13.49%-3.91%+28.29%-97.20%LEXXLexaria Bioscience+6.69%+17.01%+22.77%+4.57%-70.06%LSBLakeShore Biopharma0.00%+1.69%+26.79%-16.00%-82.13%ONCOOnconetix-3.14%-5.12%-5.44%-55.86%-99.37%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCYCCCyclacel Pharmaceuticals 2.00HoldN/AN/ALEXXLexaria Bioscience 3.00Buy$4.00288.35% UpsideLSBLakeShore Biopharma 0.00N/AN/AN/AONCOOnconetix 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest ONCO, LEXX, LSB, and CYCC Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/29/2025LEXXLexaria BioscienceHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$5.00 ➝ $4.007/1/2025LEXXLexaria BioscienceHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$7.00 ➝ $5.00(Data available from 9/6/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCYCCCyclacel Pharmaceuticals$10K1,594.17N/AN/A($58.87) per share-0.12LEXXLexaria Bioscience$460K43.80N/AN/A$0.48 per share2.15LSBLakeShore Biopharma$85.67M0.20N/AN/A$3.35 per share0.25ONCOOnconetix$1.33M3.24N/AN/A$11.22 per share0.25Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCYCCCyclacel Pharmaceuticals-$11.21M-$839.58N/A∞N/AN/A-723.64%-145.51%11/10/2025 (Estimated)LEXXLexaria Bioscience-$5.80M-$0.67N/AN/AN/A-1,849.19%-157.22%-133.69%11/25/2025 (Estimated)LSBLakeShore Biopharma-$13.93MN/A0.00∞N/AN/AN/AN/A10/30/2025 (Estimated)ONCOOnconetix-$58.69MN/A0.00∞N/A-3,327.03%-192.74%-89.55%N/ALatest ONCO, LEXX, LSB, and CYCC EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/14/2025Q2 2025ONCOOnconetixN/A-$4.05N/A-$4.76N/A$0.11 million8/13/2025Q2 2025CYCCCyclacel Pharmaceuticals-$72.00-$0.98+$71.02-$0.98$0.03 millionN/A7/14/2025Q3 2025LEXXLexaria Bioscience-$0.15-$0.21-$0.06-$0.21$0.17 million$0.17 million6/12/2025Q1 2025ONCOOnconetixN/A$21.25N/A-$0.53N/A$0.10 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCYCCCyclacel Pharmaceuticals$0.152.11%N/AN/A N/ALEXXLexaria BioscienceN/AN/AN/AN/AN/ALSBLakeShore BiopharmaN/AN/AN/AN/AN/AONCOOnconetixN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCYCCCyclacel PharmaceuticalsN/A5.775.77LEXXLexaria BioscienceN/A3.903.90LSBLakeShore Biopharma0.051.020.75ONCOOnconetixN/A0.070.06Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCYCCCyclacel Pharmaceuticals23.58%LEXXLexaria Bioscience13.06%LSBLakeShore Biopharma52.64%ONCOOnconetix23.89%Insider OwnershipCompanyInsider OwnershipCYCCCyclacel Pharmaceuticals51.20%LEXXLexaria Bioscience26.40%LSBLakeShore BiopharmaN/AONCOOnconetix3.10%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCYCCCyclacel Pharmaceuticals142.24 million1.09 millionOptionableLEXXLexaria Bioscience719.56 million14.40 millionNot OptionableLSBLakeShore Biopharma77320.77 millionN/AN/AONCOOnconetix121.55 million1.50 millionN/AONCO, LEXX, LSB, and CYCC HeadlinesRecent News About These CompaniesOnconetix (NASDAQ:ONCO) Shares Down 2.3% - Should You Sell?August 30, 2025 | americanbankingnews.comOnconetix Director Resignation Amid Financial AdjustmentsAugust 12, 2025 | msn.com$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Onconetix, Inc. (NASDAQ: ONCO)July 17, 2025 | globenewswire.comOnconetix, Inc.: Onconetix and Ocuvex Therapeutics announce execution of definitive merger agreementJuly 16, 2025 | finanznachrichten.deOnconetix Shares Touch All-Time Low on Reverse Merger With OcuvexJuly 16, 2025 | marketwatch.comONCO Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of Onconetix, Inc. Is Fair to ShareholdersJuly 16, 2025 | businesswire.comOnconetix and Ocuvex Therapeutics announce execution of definitive merger agreementJuly 16, 2025 | globenewswire.comOnconetix, Inc. Announces Positive Decision by Nasdaq Hearings PanelJune 16, 2025 | globenewswire.comOnconetix, Inc. Announces Approval of 1-for-85 Reverse Stock Split by StockholdersJune 13, 2025 | nasdaq.comOnconetix, Inc. Announces 1-for-85 Reverse Stock Split and Results of the Special Meeting of StockholdersJune 11, 2025 | globenewswire.comOnconetix faces potential Nasdaq delisting over filing delaysMay 24, 2025 | investing.comOnconetix receives additional delisting notice from NasdaqMay 23, 2025 | finance.yahoo.comOnco-Innovations Announces Appointment of Professor Steven Jones as Senior Scientific Advisor, Strengthening Technical Acumen in AI-Powered Precision OncologyMay 22, 2025 | accessnewswire.comAOnconetix, Inc. Announces Receipt of Additional Notice from NasdaqMay 22, 2025 | globenewswire.comOnco-Innovations Uplists to Cboe CanadaMay 22, 2025 | businesswire.comOnconetix, Inc. Announces Receipt of Additional Notice from NasdaqApril 30, 2025 | globenewswire.comOnconetix faces third delisting threat since 2022 IPOApril 21, 2025 | bizjournals.comOnco-Innovations Announces Partnership with Dalton Pharma for Isotope Synthesis of Patented PNKP TechnologyApril 17, 2025 | accessnewswire.comAOnco-Innovations Announces Private PlacementApril 16, 2025 | accessnewswire.comAOnconetix Inks Letter Of Intent For Potential Business Combination With OcuvexApril 10, 2025 | nasdaq.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeONCO, LEXX, LSB, and CYCC Company DescriptionsCyclacel Pharmaceuticals NASDAQ:CYCC$7.12 -0.34 (-4.56%) Closing price 09/5/2025 04:00 PM EasternExtended Trading$7.12 +0.00 (+0.07%) As of 09/5/2025 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Cyclacel Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer and other proliferative diseases in the United States, the United Kingdom, and internationally. The company's lead product includes fadraciclib, a cyclin dependent kinase Inhibitors (CDK) that is in Phase 1/2 clinical trial for the treatment of solid tumors and hematological malignancies, as well as in combination with venetoclax to treat relapsed or refractory chronic lymphocytic leukemia; and Plogosertib, a polo-like kinase inhibitor program, which is in Phase 1/2 clinical trial for the treatment of advanced solid tumors and hematological malignancies. It has a clinical collaboration agreement with the University of Texas MD Anderson Cancer Center to clinically evaluate the safety and efficacy of three cyclacel medicines in patients with hematological malignancies, including chronic lymphocytic leukemias, acute myeloid leukemias, myelodysplastic syndromes, and other advanced leukemias. The company was founded in 1996 and is headquartered in Berkeley Heights, New Jersey.Lexaria Bioscience NASDAQ:LEXX$1.03 +0.06 (+6.69%) Closing price 09/5/2025 04:00 PM EasternExtended Trading$1.02 -0.01 (-1.36%) As of 09/5/2025 07:54 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Lexaria Bioscience Corp. operates as a biotechnology company. It develops and out-licenses its patented drug delivery technology, DehydraTECH, which combines lipophilic molecules or active pharmaceutical ingredients with specific long-chain fatty acids and carrier compounds that improve the way they enter the bloodstream, increasing their effectiveness and allowing for lower overall dosing while promoting healthier oral ingestion methods. The company's DehydraTECH is used with a range of active molecules encompassing fat-soluble vitamins, pain medications, hormones, PDE5 inhibitors, antivirals, oral nicotine and its analogs, and cannabinoids. Its DehydraTECH technology evaluates therapeutic indications, including hypertension, heart disease, and diabetes; and is suitable for a variety of product formats, such as pharmaceuticals, nutraceuticals, over the counter, and consumer packaged goods. Lexaria Bioscience Corp. was incorporated in 2004 and is headquartered in Kelowna, Canada.LakeShore Biopharma NASDAQ:LSB$0.84 0.00 (0.00%) Closing price 09/5/2025 03:54 PM EasternExtended Trading$0.84 0.00 (0.00%) As of 09/5/2025 07:09 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.LakeShore Biopharma Co., Ltd. engages in the provision of discovering, developing, manufacturing, and commercializing vaccines and therapeutic biologics for infectious diseases and cancer. It focuses on developing PIKA technology platform. It operates through the People's Republic of China and Other Countries or Regions. The company was founded by Yi Zhang on November 16, 2020 and is headquartered in Beijing, China.Onconetix NASDAQ:ONCO$2.78 -0.09 (-3.14%) Closing price 09/5/2025 04:00 PM EasternExtended Trading$2.81 +0.03 (+1.08%) As of 09/5/2025 07:50 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Onconetix, Inc., a biotechnology company, focuses on the research, development, and commercialization of solutions for men's health and oncology. It offers Entadfi, an FDA-approved, once daily pill that combines finasteride and tadalafil for the treatment of benign prostatic hyperplasia; and Proclarix, an in vitro protein-based blood diagnostic test for prostate cancer. The company was formerly known as Blue Water Biotech, Inc. and changed its name to Onconetix, Inc. in December 2023. Onconetix, Inc. was incorporated in 2018 and is headquartered in Cincinnati, Ohio. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 09/01 - 09/05 Lululemon Share Price Has Plenty of Room Left to Fall Why DocuSign Could Be a SaaS Value Play After Q2 Earnings Why Hedge Fund Elliott Bet $4B on Pepsi and Sees Over 50% Upside Palantir Insider Selling: Risk Signal or Normal Activity? Advanced Micro Devices' 2026 Forecasts Are Way Too Low Salesforce Stumbles, But Investors Eye a Major Comeback Buy the Dip? GitLab’s Bullish Case Outweighs the Bears Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
